Evidence map›Paper›PMID 42491740›Full record

ArticleJournal of education and health promotion2026

Investigation of secondary hyperparathyroidism and its contributing factors in hemodialysis patients: A cross-sectional study.

Mahdieh Jamshidi, Golamreza Bazmandegan, Zahra Kamiab, Mohammad Rasool Dehghani Firouzabadi, Mohammad Ali Zakeri, Alaa Hamza Hermis, Saadya Hadi Humade, Mahmood Kahnooji

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of education and health promotion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mahdieh JamshidiDepartment of Internal Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Golamreza BazmandeganPhysiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Zahra KamiabDepartment of Community Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Mohammad Rasool Dehghani FirouzabadiNon-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Mohammad Ali ZakeriNursing Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Alaa Hamza HermisNursing College, Al-Qadisiyah University, AL-Dewaynia, Iraq.
Saadya Hadi HumadeNursing College, Al-Mustaqbal University, 51001 Hillah, Babil, Iraq.
Mahmood KahnoojiSocial Determinants of Health Research Centre, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHemodialysis may lead to changes in serum levels of important parameters such as calcium and phosphorus, which can also affect the level of parathyroid hormone. The present study aimed to determine the prevalence and some causes of secondary hyperparathyroidism (SHPT) in hemodialysis patients. MATERIALS AND

methodsThe population of this descriptive-cross-sectional study included 60 hemodialysis patients admitted to the hospital in the southeast of Iran, all of whom were enrolled in the study through convenience sampling. Sociodemographic characteristics, hematologic and biochemical indices, and serum parathyroid hormone (PTH) levels were examined. A PTH hormone cut-off level of 300 picograms per deciliter was considered. Data were analyzed using an independent

resultThe mean age of the participants was 53.16 ± 8.60 years. Among these, 34 (56.7%) were diagnosed with SHPT, and 58 (96.7%) had underlying diseases. Additionally, 17 (28.3%) had abnormal calcium levels, 40 (66.7%) had abnormal phosphorus levels, four (6.7%) had abnormal alkaline phosphatase (ALP), and 19 (31.7%) had abnormal Ca × P. The mean levels of PTH (

conclusionBased on the results of this study, the higher levels of ALP in hemodialysis patients with SHPT suggest that regular monitoring of laboratory tests, particularly alkaline phosphatase, can be beneficial in the follow-up of these patients.

Indexed as

Calcium-phosphate metabolismchronic kidney diseasehemodialysissecondary hyperparathyroidismvitamin D deficiency

Identifiers

PMID42491740
PMCPMC13378853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.